MBM Wealth Consultants LLC Makes New $220,000 Investment in Danaher Co. (NYSE:DHR)

MBM Wealth Consultants LLC acquired a new position in shares of Danaher Co. (NYSE:DHR) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 793 shares of the conglomerate’s stock, valued at approximately $220,000.

Several other hedge funds also recently modified their holdings of the stock. Benjamin Edwards Inc. grew its holdings in Danaher by 1.8% in the second quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock worth $538,000 after purchasing an additional 38 shares during the period. Patrick M Sweeney & Associates Inc. grew its stake in shares of Danaher by 3.4% in the 2nd quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock valued at $307,000 after buying an additional 40 shares during the period. Trust Co of Kansas increased its position in Danaher by 4.1% in the 2nd quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock valued at $255,000 after buying an additional 40 shares in the last quarter. Abacus Planning Group Inc. raised its stake in Danaher by 0.7% during the 2nd quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock worth $1,359,000 after buying an additional 40 shares during the period. Finally, Certified Advisory Corp raised its stake in Danaher by 4.5% during the 2nd quarter. Certified Advisory Corp now owns 926 shares of the conglomerate’s stock worth $231,000 after buying an additional 40 shares during the period. Institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In related news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the transaction, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now owns 20,230 shares in the company, valued at $5,566,486.80. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock valued at $11,042,433 in the last quarter. 11.10% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have recently commented on DHR. TD Cowen boosted their price objective on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. Stephens began coverage on shares of Danaher in a research note on Tuesday, October 1st. They set an “overweight” rating and a $315.00 price target for the company. Evercore ISI lifted their price objective on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. The Goldman Sachs Group raised their price target on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $300.00 price objective on shares of Danaher in a report on Friday, September 6th. Seven equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average price target of $282.12.

Danaher Price Performance

Shares of NYSE DHR opened at $268.79 on Tuesday. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The stock has a fifty day simple moving average of $271.07 and a two-hundred day simple moving average of $258.64. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70. The firm has a market cap of $199.09 billion, a price-to-earnings ratio of 45.56, a price-to-earnings-growth ratio of 4.55 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the previous year, the firm posted $2.05 earnings per share. The company’s quarterly revenue was down 2.9% compared to the same quarter last year. Analysts anticipate that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be paid a $0.27 dividend. The ex-dividend date is Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.40%. Danaher’s dividend payout ratio is currently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.